![](/img/cover-not-exists.png)
O-008 * Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)
Rimassa, L., Bozzarelli, S., Cordio, S., Toppo, L., Lonardi, S., Zaniboni, A., Bordonaro, R., Liguigli, W., Zagonel, V., Tronconi, M. C., Di Tommaso, L., Giordano, L., Santoro, A.Volume:
26
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv235.07
Date:
June, 2015
File:
PDF, 37 KB
2015